Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00305110 · ClinicalTrials.gov registry record · Phase 2

Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain

A Phase 2 study of Acute Pain, sponsored by Montefiore Medical Center.

Completed
Registry status
Phase 2
Development phase
298
Enrollment target
1
Study location

NCT00305110 is a Phase 2 study of Acute Pain that has completed, run by Montefiore Medical Center. The registered enrollment target is 298 participants, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (14% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00305110, a Phase 2 study of Acute Pain, has completed, sponsored by Montefiore Medical Center.

COMPLETED
Registry status
Phase 2
Development phase
298 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the safety and speed of onset of 2mg intravenous hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency department with acute severe pain

Conditions Studied

Interventions

  • DRUG 2 mg IV hydromorphone

Study Locations (1)

New York

  • Montefiore Medical Center - The Bronx

Trial Details

FieldValue
Enrollment Target 298 participants
Start Date 2006-01
Est. Completion 2006-10
Phase Phase 2

Sponsor

Montefiore Medical Center

345 total trials

What the Registry Record Tells You About NCT00305110

The ClinicalTrials.gov registry entry for NCT00305110 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 262-participant average among 50 other Acute Pain trials with a reported enrollment target (14% higher). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Pain appearing as the primary indexed condition, and to 1 intervention - of which 2 mg IV hydromorphone is the first listed.

NCT00305110 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00305110 about?

NCT00305110 is a clinical study titled "Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain". The purpose of this study is to determine the safety and speed of onset of 2mg intravenous hydromorphone (Dilaudid) in patients weighing at least 150 lbs presenting to the emergency department with acute severe pain

What is the current status of trial NCT00305110?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2006-01. Estimated completion is 2006-10.

What conditions does trial NCT00305110 study?

This clinical trial studies the following conditions: Acute Pain.

What interventions are being tested in trial NCT00305110?

The interventions under investigation include: 2 mg IV hydromorphone (DRUG).

Who is sponsoring clinical trial NCT00305110?

This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00305110 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acute Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.